CD274 and neoplasm: Different biomarkers have been investigated to predict the efficacy and prognosis, such as PD-L1 expression and copy number gains (1–4, 8–11), tumor mutation burden (TMB) (12–14), microsatellite instability (MSI) (15), tumor infiltrating lymphocytes (16–18) and inflammatory cytokines (19).